Please note that this product (marketed as Jinarc) was withdrawn from the Community Register of designated orphan medicinal products in March 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 5 August 2013, orphan designation (EU/3/13/1175) was granted by the European Commission to Otsuka Pharmaceutical Europe Ltd, United Kingdom, for tolvaptan for the treatment of autosomal dominant polycystic kidney disease.
|Disease / condition||
Treatment of autosomal dominant polycystic kidney disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.